Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 5/2024

Open Access 21-03-2024 | Autoimmune Encephalitis | Review

Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis

Authors: Maayan J. Yakir, MD, Jennifer H. Yang, MD

Published in: Current Treatment Options in Neurology | Issue 5/2024

Login to get access

Abstract

Purpose of review

Autoimmune encephalitis (AE) is increasingly recognized as a treatable cause of encephalitis in children. While prior observational studies demonstrate improved motor outcomes with early immunotherapy, less is known about long-term management and treatment for relapsing disease. In this review, we present current treatment approaches to pediatric AE, in particular relapse risk and treatment for relapsing AE in children.

Recent findings

A recent meta-analysis of anti-NMDAR encephalitis demonstrated that disease onset in adolescence was associated with an increased odds of relapse whereas treatment with rituximab and IVIG for 6 months or longer were associated with a non-relapsing course. However, no specific pediatric sub-analyses were reported. A single-center study on adult and pediatric AE showed that rituximab use was associated with a reduction in time to relapse and recurring relapses although the data for the pediatric cohort did not achieve statistical significance.

Summary

The use of second-line immunotherapy during the initial attack may reduce the risk for relapsing disease in pediatric AE. Larger studies are needed to investigate relapse risk and treatment in both anti-NMDAR and non-NMDAR encephalitis in children.
Literature
1.
Cellucci T, Van MH, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e663.PubMedPubMedCentralCrossRef
2.
3.
Dubey D, Pittock S, Kelly C, McKeon A, Lopez-Chiriboga A, Lennon V, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166–77.PubMedPubMedCentralCrossRef
4.
de Bruijn M, Bruijstens A, Bastiaansen A, van Sonderen A, Schreurs M, Smitt PS, et al. Pediatric autoimmune encephalitis: recognition and diagnosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e682.PubMedPubMedCentralCrossRef
5.
Yang J, Graves J. Anti-NMDA receptor encephalitis. In: Handbook of pediatric epilepsy case studies. 2nd ed. CRC Press; 2023.
6.
•• Yang JH, Liu EN, Nguyen L, Dunn-Pirio A, Graves J. Survival analysis of immunotherapy effects on relapse rate in pediatric and adult autoimmune encephalitis. Neurology. 2023. https://​doi.​org/​10.​1212/​WNL.​0000000000207746​. A single center cohort study demonstrating an overall lower relapse risk with rituximab use at the time of initial presentation of autoimmune encephalitis. However, the data for relapse reduction in children and in anti-NMDARE specifically are unclear.
7.
Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, et al. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052.PubMedPubMedCentralCrossRef
8.
Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–57.PubMedCrossRef
9.
Boesen M, Born A, Lydolph M, Blaabjerg M, Børresen M. Pediatric autoimmune encephalitis in Denmark during 2011–17: a nationwide multicenter population-based cohort study. Eur J Paediatr Neurol. 2019;23(4):639–52.PubMedCrossRef
10.
Cucuzza M, Pavone P, D’Ambra A, Finocchiaro M, Greco F, Smilari P, et al. Autoimmune encephalitis and CSF anti-AMPA GluR3 antibodies in childhood: a case report and literature review. Neurol Sci. 2022;43(9):5237–41.PubMedCrossRef
11.
12.
Theroux LM, Goodkin HP, Heinan KC, Quigg M, Brenton JN. Extreme delta brush and distinctive imaging in a pediatric patient with autoimmune GFAP astrocytopathy. Mult Scler Relat Disord. 2018;26:121–3.PubMedCrossRef
13.
Gravier-Dumonceau A, Ameli R, Rogemond V, Ruiz A, Joubert B, Muñiz-Castrillo S, et al. Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology. 2022;98(6):e653–68.PubMedPubMedCentralCrossRef
14.
Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.PubMedCrossRef
15.
Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, et al. Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol. 2018;15(321):157–63.CrossRef
16.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268–82.PubMedCrossRef
17.
Gabilondo I, Saiz A, Galán L, González V, Jadraque R, Sabater L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996–9.PubMedCrossRef
18.
Florance N, Davis R, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11–8.PubMedPubMedCentralCrossRef
19.
Titulaer M, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol. 2013;12(2):157–65.PubMedPubMedCentralCrossRef
20.
Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P, Carr A, Sheerin UM, Press R, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe WVA. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178–92.PubMedPubMedCentralCrossRef
21.
Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234–46.PubMedCrossRef
22.
23.
Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73:1297–307.PubMedCrossRef
24.
•• Nosadini M, Granata T, Matricardi S, Freri E, Ragona F, Papetti L, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61:1101–7. This is a meta-analysis of anti-NMDAR encephalitis demonstrating that disease onset in adolescence was associated with an increased odds of relapse whereas treatment with rituximab and IVIG for 6 months or longer were associated with a non-relapsing course. However, no specific pediatric sub-analyses were reported.
25.
Gastaldi M, Mariotto S, Giannoccaro MP, Iorio R, Zoccarato M, Nosadini M, et al. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. Eur J Neurol. 2020;27(4):633–43.PubMedCrossRef
26.
Lee S, Kim HD, Lee JS, Kang H. Clinical features and treatment outcomes of seronegative pediatric autoimmune encephalitis. J Clin Neurol. 2021;17(2):300–6.PubMedPubMedCentralCrossRef
27.
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, et al. Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 2021;78(11):1333–44.PubMedCrossRef
28.
Nosadini M, Mohammad S, Ramanathan S, Brilot F, Dale R. Immune therapy in autoimmune encephalitis: a systemic review. Expert Rev Neurother. 2015;15(12):1391–419.PubMedCrossRef
29.
van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449–56.PubMedCrossRef
30.
Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016;86(18):1683–91.PubMedCrossRef
31.
32.
Goenka A, Chikkannaiah M, Kumar G. Pediatric auto-immune encephalitis. Curr Probl Pediatr Adolesc Health Care. 2021;51:101031.PubMedCrossRef
33.
Co DO, Kwon JM. Autoimmune encephalitis: distinguishing features and specific therapies. Crit Care Clin. 2022;38:393–412.PubMedCrossRef
34.
35.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.PubMedCrossRef
36.
McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, et al. Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open. 2021;4(3):e2036321.PubMedPubMedCentralCrossRef
37.
Oh M, Lee H. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol. 2013;19(1):51–9.PubMedPubMedCentralCrossRef
38.
39.
Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Tocilizumab in Autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824–32.PubMedPubMedCentralCrossRef
40.
Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, et al. teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2021;18(1):474–87.PubMedCrossRef
41.
Jaafar F, Haddad L, Koleilat N, Sharara-Chami R, Shbarou R. Super refractory status epilepticus secondary to anti-GAD antibody encephalitis successfully treated with aggressive immunotherapy. Epilepsy Behav Rep. 2020;14:100396.PubMedPubMedCentralCrossRef
42.
Cordani R, Micalizzi C, Giacomini T, Gastaldi M, Franciotta D, Fioredda F, et al. Bortezomib-responsive refractory anti-N-methyl-D-asparte receptor encephalitis. Pediatr Neurol. 2020;103:61–4.PubMedCrossRef
43.
Schroeder C, Back C, Koc U, Strassburger-krogias K, Reinacher-schick A, Gold R, et al. Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clin Neurol Neurosurg. 2018;172:24–6.PubMedCrossRef
44.
Lazzarin SM, Vabanesi M, Cecchetti G, Fazio R, Fanelli GF, Volonté MA, et al. Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. J Neurol. 2021;268(2):741–2.PubMedCrossRef
45.
Wang T, Wang B, Zeng Z, Li H, Zhang F, Ruan X, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study. J Neuroimmunol. 2021;354:577527.PubMedCrossRef
46.
Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M, Church AJ, Vincent A, Zandi MLM. Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Eur J Neurol. 2018;25(11):1384–8.PubMedCrossRef
47.
Scheibe F, Prüss H, Mengel AM, Kohler S, Nümann A, Köhnlein M, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366–70.PubMedCrossRef
48.
Behrendt V, Krogias C, Reinacher-Schick A, Gold RKI. Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2016;73(10):1251–3.PubMedCrossRef
49.
Wong K-H, Day G, Titulaer M, Torner J, Cudkowicz M, Coffey C, et al. The ExTINGUISH trial: a Phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis. Neurology. 2022;99:S39–40.CrossRef
50.
Scheibe F, Ostendorf L, Prüss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847–54.PubMedCrossRef
51.
Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–68.PubMedCrossRef
52.
Gombolay G, Brenton JN, Yang JH, Stredny CM, Kammeyer R, Otten CE, et al. MRI features and their association with outcomes in children with anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200130.PubMedPubMedCentralCrossRef
53.
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt 8):1831–44.PubMedCrossRef
54.
Kim H, Yum MS, Kim MJ, Ko TS. A Rare Case of Anti-Ma2 antibody-mediated autoimmune encephalomyelitis in childhood. Ann Child Neurol. 2022;30(3):148–51.CrossRef
Metadata
Title
Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis
Authors
Maayan J. Yakir, MD
Jennifer H. Yang, MD
Publication date
21-03-2024
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 5/2024
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-024-00786-7
Image Credits